{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:33:15Z","timestamp":1793885595360,"version":"4.8.0"},"reference-count":246,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":288,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiovascular Magnetic Resonance"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.jocmr.2026.102818","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:52:20Z","timestamp":1792597940000},"page":"102818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular magnetic resonance imaging in cardio-oncology: An expert consensus statement from the Society for Cardiovascular Magnetic Resonance. Endorsed by the International Cardio-Oncology Society (ICOS)"],"prefix":"10.1016","volume":"28","author":[{"given":"Lauren A.","family":"Baldassarre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-2470","authenticated-orcid":false,"given":"Samuel W.","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1001-1849","authenticated-orcid":false,"given":"Jennifer H.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-5637","authenticated-orcid":false,"given":"W. Patricia","family":"Bandettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9935-8904","authenticated-orcid":false,"given":"Ana","family":"Barac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bucciarelli-Ducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliano","family":"de Lara Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-9340","authenticated-orcid":false,"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-7634","authenticated-orcid":false,"given":"Vanessa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luba","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Gregory","family":"Hundley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad H.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Leiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lopez-Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-5615","authenticated-orcid":false,"given":"Vineeta","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Rochitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Schulz-Menger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Barbara","family":"Srichai-Parsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-4785","authenticated-orcid":false,"given":"Olga","family":"Toro-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weinsaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-7090","authenticated-orcid":false,"given":"Charlotte","family":"Manisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jocmr.2026.102818_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11864-019-0672-z","article-title":"Advanced imaging modalities to monitor for cardiotoxicity","volume":"20","author":"Seraphim","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jcmg.2018.06.004","article-title":"Cardiovascular magnetic resonance in the oncology patient","volume":"11","author":"Jordan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdq609","article-title":"Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper","volume":"22","author":"Aapro","year":"2011","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient","volume":"11","author":"Plana","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"10.1016\/j.jocmr.2026.102818_bib8","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"10.1016\/j.jocmr.2026.102818_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American heart association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12968-017-0327-9","article-title":"Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort","volume":"19","author":"Petersen","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"16","key":"10.1016\/j.jocmr.2026.102818_bib12","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","article-title":"Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?","volume":"21","author":"Bellenger","year":"2000","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.jocmr.2026.102818_bib13","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"41","key":"10.1016\/j.jocmr.2026.102818_bib15","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","article-title":"Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial","volume":"45","author":"Marwick","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","article-title":"Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing","volume":"22","author":"Schulz-Menger","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib17","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.amjcard.2017.02.008","article-title":"Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment","volume":"119","author":"Melendez","year":"2017","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.jocmr.2026.102818_bib18","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.117.027930","article-title":"Early Myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: the need to interpret left ventricular strain with volumes","volume":"135","author":"Jordan","year":"2017","journal-title":"Circulation."},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","article-title":"Left ventricular mass change after anthracycline chemotherapy","volume":"11","author":"Jordan","year":"2018","journal-title":"Circulation Heart failure"},{"issue":"11","key":"10.1016\/j.jocmr.2026.102818_bib20","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","article-title":"Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines","volume":"110","author":"Neilan","year":"2012","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12968-018-0484-5","article-title":"Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification","volume":"20","author":"Puntmann","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"issue":"6","key":"10.1016\/j.jocmr.2026.102818_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.121.012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial Strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up","volume":"14","author":"Giusca","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jocmr.2026.102818_bib24","article-title":"Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography","author":"Houbois","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5603\/CJ.a2016.0023","article-title":"Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method","volume":"23","author":"Nakano","year":"2016","journal-title":"Cardiol J."},{"key":"10.1016\/j.jocmr.2026.102818_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2018.03.041","article-title":"Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy","volume":"261","author":"Ong","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12968-017-0373-3","article-title":"Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy","volume":"19","author":"Jolly","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10554-018-1482-2","article-title":"Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study","volume":"35","author":"Gong","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jocmr.2026.102818_bib30","article-title":"Cardiac magnetic resonance imaging for the assessment of the myocadium following doxorubicin-based chemotherapy","author":"Lunning","year":"2013","journal-title":"Am J Clin Onc"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015400","article-title":"Simultaneous Left Ventricular Volume and Strain Changes During Chemotherapy Associate With 2-Year Postchemotherapy Measures of Left Ventricular Ejection Fraction","volume":"9","author":"Suerken","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12968-021-00740-5","article-title":"Defining the optimal temporal and spatial resolution for cardiovascular magnetic resonance imaging feature tracking","volume":"23","author":"Backhaus","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.21037\/cdt-20-165","article-title":"The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology","volume":"10","author":"Burrage","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","article-title":"Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update","volume":"22","author":"Kramer","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.004325","article-title":"Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors","volume":"9","author":"Jordan","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jocmr.2026.102818_bib36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jcmg.2016.06.006","article-title":"Progressive 3-month increase in LV myocardial ECV after anthracycline-based chemotherapy","volume":"10","author":"Melendez","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jocmr.2026.102818_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2018.10.023","article-title":"CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping","volume":"275","author":"Haslbauer","year":"2019","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.118.008777","article-title":"Early detection of anthracycline-induced cardiotoxicity in breast cancer survivors with T2 cardiac magnetic resonance","volume":"12","author":"Lustberg","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","article-title":"Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity","volume":"73","author":"Galan-Arriola","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib40","first-page":"620","article-title":"Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC","volume":"5","author":"Muehlberg","year":"2018","journal-title":"Heart Fail"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib41","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jcmg.2019.10.016","article-title":"Can quantitative CMR tissue characterization adequately identify cardiotoxicity during chemotherapy?: impact of temporal and observer variability","volume":"13","author":"Altaha","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"20","key":"10.1016\/j.jocmr.2026.102818_bib42","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.jacc.2017.03.560","article-title":"Late anthracycline-related cardiotoxicity in low-risk breast cancer patients","volume":"69","author":"Maestrini","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12410-019-9521-5","article-title":"Clinical and advanced MRI techniques for detection of checkpoint inhibitor associated myocarditis","volume":"13","author":"Arbune","year":"2020","journal-title":"Curr Cardiovasc Imaging Rep"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib45","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"9_ement_1","key":"10.1016\/j.jocmr.2026.102818_bib47","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0735-1097(19)31283-5","article-title":"Late gadolinium enhancement in patients with myocarditis from immune checkpoint inhibitors","volume":"73","author":"Zhang","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jacc.2018.10.038","volume":"73","author":"Doherty","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib49","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/ehjci\/jew081","article-title":"EACVI appropriateness criteria for the use of cardiovascular imaging in heart failure derived from European National Imaging Societies voting","volume":"17","author":"Garbi","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"40","key":"10.1016\/j.jocmr.2026.102818_bib50","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the management of myocarditis and pericarditis","volume":"46","author":"Schulz-Menger","year":"2025","journal-title":"Eur Heart J."},{"issue":"36","key":"10.1016\/j.jocmr.2026.102818_bib51","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation."},{"issue":"9","key":"10.1016\/j.jocmr.2026.102818_bib53","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"Celutkiene","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jaccao.2020.04.011","article-title":"Magnetic resonance imaging to detect cardiovascular effects of cancer therapy: JACC cardiooncology state-of-the-art review","volume":"2","author":"Harries","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/ehjci\/jeaa345","article-title":"Role of cardiovascular magnetic resonance imaging in cardio-oncology","volume":"22","author":"Saunderson","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"17","key":"10.1016\/j.jocmr.2026.102818_bib56","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"Cardiovascular magnetic resonance in myocarditis: a JACC white paper","volume":"53","author":"Friedrich","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jocmr.2026.102818_bib57","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib58","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive Meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jocmr.2026.102818_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.jocmr.2026.102818_bib60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11912-018-0718-6","article-title":"Immune checkpoint inhibitor toxicity","volume":"20","author":"Palmieri","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"16","key":"10.1016\/j.jocmr.2026.102818_bib61","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jocmr.2026.102818_bib62","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.jocmr.2026.102818_bib63","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib64","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jocmr.2026.102818_bib65","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","article-title":"Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis","volume":"70","author":"Grani","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jocmr.2026.102818_bib66","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10554-019-01552-6","article-title":"Incremental value of extracellular volume assessment by cardiovascular magnetic resonance imaging in risk stratifying patients with suspected myocarditis","volume":"35","author":"Grani","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.jocmr.2026.102818_bib67","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246764","article-title":"Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity","volume":"16","author":"Higgins","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jocmr.2026.102818_bib70","unstructured":"National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER) Program: Age and Cancer. [March 5, 2021:[Available from: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/age."},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib71","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","article-title":"2025 Heart disease and stroke statistics: a report of US and global data from the American heart association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.jocmr.2026.102818_bib72","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation."},{"issue":"30","key":"10.1016\/j.jocmr.2026.102818_bib73","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"9544","key":"10.1016\/j.jocmr.2026.102818_bib75","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jocmr.2026.102818_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.11.174","article-title":"Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond","volume":"227","author":"Di Lisi","year":"2017","journal-title":"Int J Cardiol"},{"issue":"20","key":"10.1016\/j.jocmr.2026.102818_bib77","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jocmr.2026.102818_bib78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib79","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12032-019-1295-8","article-title":"Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment","volume":"36","author":"Gara","year":"2019","journal-title":"Med Oncol"},{"issue":"36","key":"10.1016\/j.jocmr.2026.102818_bib80","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J."},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib81","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jocmr.2026.102818_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2025.101940","article-title":"SCMR Expert consensus statement on quantitative myocardial perfusion cardiovascular magnetic resonance imaging","author":"Chiribiri","year":"2025","journal-title":"J Cardiovasc Magn Reson"},{"issue":"22","key":"10.1016\/j.jocmr.2026.102818_bib83","first-page":"e368","article-title":"2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: a report of the American College of Cardiology\/American heart association joint committee on clinical practice guidelines","volume":"144","author":"Gulati","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib84","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/jmri.26668","article-title":"Quantitative myocardial perfusion in coronary artery disease: A perfusion mapping study","volume":"50","author":"Knott","year":"2019","journal-title":"J Magn Reson Imaging"},{"issue":"19","key":"10.1016\/j.jocmr.2026.102818_bib85","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/heartjnl-2024-325535","article-title":"Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging","volume":"111","author":"Dobbin","year":"2025","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib86","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jcmg.2018.12.022","article-title":"Automated pixel-wise quantitative myocardial perfusion mapping by CMR to detect obstructive coronary artery disease and coronary microvascular dysfunction: validation against invasive coronary physiology","volume":"12","author":"Kotecha","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"10.1016\/j.jocmr.2026.102818_bib87","first-page":"1282","article-title":"The prognostic significance of quantitative myocardial perfusion: an artificial intelligence-based approach using perfusion mapping","volume":"141","author":"Knott","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.jocmr.2026.102818_bib88","first-page":"7","article-title":"Takotsubo cardiomyopathy in cancer patients","volume":"5","author":"Desai","year":"2019","journal-title":"Cardiooncology"},{"issue":"6","key":"10.1016\/j.jocmr.2026.102818_bib89","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib90","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2009.23.8527","article-title":"Aortic stiffness increases upon receipt of anthracycline chemotherapy","volume":"28","author":"Chaosuwannakit","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib91","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015609","article-title":"Promotion of Arterial stiffness by childhood cancer and its characteristics in adult long-term survivors","volume":"10","author":"Arnold","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib92","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/pbc.25547","article-title":"Arterial stiffness in childhood cancer survivors","volume":"62","author":"Krystal","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib93","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/imj.12645","article-title":"Early and late changes in markers of aortic stiffness with breast cancer therapy","volume":"45","author":"Grover","year":"2015","journal-title":"Intern Med J"},{"issue":"14","key":"10.1016\/j.jocmr.2026.102818_bib94","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2010.12.017","article-title":"Aortic stiffness: current understanding and future directions","volume":"57","author":"Cavalcante","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jocmr.2026.102818_bib95","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jacc.2010.03.083","article-title":"Iron overload cardiomyopathy: better understanding of an increasing disorder","volume":"56","author":"Gujja","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jocmr.2026.102818_bib96","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cardfail.2010.05.009","article-title":"Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment","volume":"16","author":"Murphy","year":"2010","journal-title":"J Card Fail"},{"issue":"20","key":"10.1016\/j.jocmr.2026.102818_bib97","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.111.050773","article-title":"Iron overload cardiomyopathy in clinical practice","volume":"124","author":"Kremastinos","year":"2011","journal-title":"Circulation."},{"issue":"20","key":"10.1016\/j.jocmr.2026.102818_bib98","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1161\/CIRCULATIONAHA.109.907196","article-title":"History and current impact of cardiac magnetic resonance imaging on the management of iron overload","volume":"120","author":"Wood","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jocmr.2026.102818_bib99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance","volume":"10","author":"Modell","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"issue":"9332","key":"10.1016\/j.jocmr.2026.102818_bib100","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib101","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12968-021-00765-w","article-title":"Myocardial iron overload by cardiovascular magnetic resonance native segmental T1 mapping: a sensitive approach that correlates with cardiac complications","volume":"23","author":"Meloni","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192890","article-title":"Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment","volume":"13","author":"Torlasco","year":"2018","journal-title":"PLoS One"},{"issue":"10038","key":"10.1016\/j.jocmr.2026.102818_bib104","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib106","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib107","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib108","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib109","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jocmr.2026.102818_bib110","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"25","key":"10.1016\/j.jocmr.2026.102818_bib111","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","article-title":"Myocardial edema and prognosis in amyloidosis","volume":"71","author":"Kotecha","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib112","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib113","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.jocmr.2026.102818_bib114","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"25","author":"Dorbala","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.jocmr.2026.102818_bib115","doi-asserted-by":"crossref","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-diagnostic criteria and appropriate utilization","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol Publ Am Soc Nucl Cardiol"},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib116","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2025.10.054","article-title":"Myocardial amyloid burden in transthyretin amyloidosis","volume":"87","author":"Sheikh","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jocmr.2026.102818_bib117","unstructured":"ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media 2025 2025."},{"key":"10.1016\/j.jocmr.2026.102818_bib118","unstructured":"Society for Cardiovascular Magnetic Resonance. Gadolinium Contrast Agent Safety and Significance of Recent Data on Brain and Body Deposition 2017 [Available from: https:\/\/scmr.site-ym.com\/page\/ContrastAgentSafety."},{"issue":"12","key":"10.1016\/j.jocmr.2026.102818_bib119","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11886-019-1225-6","article-title":"Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management","volume":"21","author":"Ala","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0167-5273(95)02276-3","article-title":"Cardiac disease after chest irradiation for Hodgkin's disease: incidence in 108 patients with long follow-up","volume":"49","author":"Piovaccari","year":"1995","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib121","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2011.06.016","article-title":"Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden","volume":"100","author":"McGale","year":"2011","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib122","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"42","key":"10.1016\/j.jocmr.2026.102818_bib123","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jocmr.2026.102818_bib124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1532-429X-15-91","article-title":"Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized P. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update","volume":"15","author":"Kramer","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jcmg.2011.07.010","article-title":"Simultaneous right and left heart real-time, free-breathing CMR flow quantification identifies constrictive physiology","volume":"5","author":"Thavendiranathan","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib126","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jcmg.2015.07.019","article-title":"Chemotherapy-induced valvular heart disease","volume":"9","author":"Crawford","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib127","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11936-017-0550-6","article-title":"Valvular heart disease in cancer patients: etiology, diagnosis, and management","volume":"19","author":"Stewart","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib128","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jcmg.2015.06.028","article-title":"Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: a national cross-sectional study","volume":"9","author":"Murbraech","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jocmr.2026.102818_bib129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/hrt.75.6.591","article-title":"Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study","volume":"75","author":"Lund","year":"1996","journal-title":"Heart"},{"issue":"21","key":"10.1016\/j.jocmr.2026.102818_bib130","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jocmr.2026.102818_bib131","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/pbc.22664","article-title":"Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies","volume":"55","author":"Schellong","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib132","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.amjcard.2015.11.027","article-title":"Assessment of valvular disorders in survivors of hodgkin's lymphoma treated by mediastinal radiotherapy +\/- chemotherapy","volume":"117","author":"Bijl","year":"2016","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib133","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","article-title":"Prevention, diagnosis, and management of radiation-associated cardiac disease: jacc scientific expert panel","volume":"74","author":"Desai","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib134","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.bjc.6605191","article-title":"Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study","volume":"101","author":"Wethal","year":"2009","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib135","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.athoracsur.2013.12.029","article-title":"Increased aorto-mitral curtain thickness independently predicts mortality in patients with radiation-associated cardiac disease undergoing cardiac surgery","volume":"97","author":"Desai","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"16","key":"10.1016\/j.jocmr.2026.102818_bib136","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jocmr.2026.102818_bib137","first-page":"14","article-title":"Heart valve disease: investigation by cardiovascular magnetic resonance","author":"Myerson","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"issue":"22","key":"10.1016\/j.jocmr.2026.102818_bib138","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.jacc.2014.02.536","article-title":"2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Nishimura","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib139","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12968-023-00942-z","article-title":"4D Flow cardiovascular magnetic resonance consensus statement: 2023 update","volume":"25","author":"Bissell","year":"2023","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jocmr.2026.102818_bib140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12959-016-0077-1","article-title":"Venous thromboembolism and persistent pulmonary hypertension in cancer patients: a cross-sectional study","volume":"14","author":"Wieshammer","year":"2016","journal-title":"Thromb J."},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib141","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J."},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib142","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10554-018-1428-8","article-title":"Echocardiographic assessment of right ventricular function: current clinical practice","volume":"35","author":"Schneider","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib143","first-page":"218","article-title":"Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance","volume":"147","author":"Grothues","year":"2004","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib144","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jocmr.2026.102818_bib145","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1183\/09059180.00006313","article-title":"Cardiac magnetic resonance imaging in pulmonary arterial hypertension","volume":"22","author":"Peacock","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jocmr.2026.102818_bib146","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1532-429X-14-11","article-title":"Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension","volume":"14","author":"Freed","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jocmr.2026.102818_bib147","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1532-429X-14-40","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry","volume":"14","author":"Swift","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib148","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jcmg.2013.01.013","article-title":"Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry","volume":"6","author":"Swift","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib149","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/eurheartj\/ehl477","article-title":"Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension","volume":"28","author":"van Wolferen","year":"2007","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib150","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1378\/chest.10-3277","article-title":"Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension","volume":"141","author":"Mauritz","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib151","first-page":"S53","article-title":"Imaging of the right heart--CT and CMR","volume":"32","author":"Kochav","year":"2015","journal-title":"Echocardiography"},{"issue":"11","key":"10.1016\/j.jocmr.2026.102818_bib152","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib153","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2016.12680","article-title":"Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial","volume":"316","author":"Greenwood","year":"2016","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.jocmr.2026.102818_bib154","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1056\/NEJMoa1716734","article-title":"Magnetic resonance perfusion or fractional flow reserve in coronary disease","volume":"380","author":"Nagel","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","article-title":"Radiation-associated cardiac disease: a practical approach to diagnosis and management","volume":"11","author":"Desai","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib156","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017454","article-title":"Imaging of the acute and chronic cardiovascular complications of radiation therapy","volume":"18","author":"Wilson","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib157","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ehjci\/jew335","article-title":"Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"18","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib158","doi-asserted-by":"crossref","first-page":"142","DOI":"10.14797\/mdcj-9-3-142","article-title":"The role of cardiac magnetic resonance in valvular heart disease","volume":"9","author":"Lopez-Mattei","year":"2013","journal-title":"Methodist DeBakey Cardiovasc J"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib159","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1532-429X-15-48","article-title":"Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling","volume":"15","author":"Tham","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.adro.2016.04.002","article-title":"Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging","volume":"1","author":"Huang","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jocmr.2026.102818_bib161","unstructured":"Society AC. Stem Cell Transplant for Cancer [Webpage]. 2020 [Available from: https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/treatment-types\/stem-cell-transplant\/why-stem-cell-transplants-are-used.html."},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib162","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaccao.2024.06.004","article-title":"Cardiovascular disease after hematopoietic stem cell transplantation in adults: JACC: cardiooncology state-of-the-art review","volume":"6","author":"Gent","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib163","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/bmt.2009.97","article-title":"Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation","volume":"45","author":"Peres","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib164","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.bmt.1703133","article-title":"Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997","volume":"28","author":"Murdych","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib165","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","article-title":"Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation","volume":"19","author":"Singla","year":"2013","journal-title":"Biol Blood and Marrow Transplant: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib166","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbmt.2009.05.008","article-title":"Fulminant myocarditis after allogeneic bone marrow transplantation: successful cytomegalovirus therapy and mechanical circulatory support for bridge to recovery","volume":"16","author":"Kataoka","year":"2010","journal-title":"Biol Blood and Marrow Transplant: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib167","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00007890-198410000-00023","article-title":"Lethal cardiac and cerebral toxoplasmosis in a patient with acute myeloid leukemia after successful allogeneic bone marrow transplantation","volume":"38","author":"Jehn","year":"1984","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.jocmr.2026.102818_bib168","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00392-006-0402-y","article-title":"One day from dyspnea to death--unsuccessful application of extracorporeal membrane oxygenation in toxoplasma myocarditis following bone marrow transplantation","volume":"95","author":"Hadem","year":"2006","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib169","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000881","article-title":"Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis","volume":"5","author":"Agha","year":"2018","journal-title":"Open Heart"},{"issue":"20","key":"10.1016\/j.jocmr.2026.102818_bib170","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jocmr.2026.102818_bib171","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jnci\/djn310","article-title":"Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study","volume":"100","author":"Mertens","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib172","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer","volume":"28","author":"Tukenova","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib173","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.2010.923","article-title":"Long-term cause-specific mortality among survivors of childhood cancer","volume":"304","author":"Reulen","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib174","first-page":"1","article-title":"Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy","volume":"1","author":"Toro-Salazar","year":"2015","journal-title":"Cardio-Oncol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40348-018-0084-3","article-title":"Precision medicine in pediatric oncology","volume":"5","author":"Burdach","year":"2018","journal-title":"Mol Cell Pediatr"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib176","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib177","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11936-018-0649-4","article-title":"Cardiotoxicity of novel targeted chemotherapeutic agents","volume":"20","author":"Rhea","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib178","first-page":"863","article-title":"Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond","volume":"32","author":"Moudgil","year":"2016","journal-title":"The Can J Cardiol"},{"issue":"21","key":"10.1016\/j.jocmr.2026.102818_bib179","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1111\/bph.14025","article-title":"New insights into cardiotoxicity caused by chemotherapeutic agents","volume":"174","author":"Grieve","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib180","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCULATIONAHA.109.902221","article-title":"Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice","volume":"121","author":"Huang","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jocmr.2026.102818_bib181","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","article-title":"A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer","volume":"47","author":"Aminkeng","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib182","first-page":"107","article-title":"Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia","volume":"17","author":"Krajinovic","year":"2017","journal-title":"Pharm J"},{"issue":"13","key":"10.1016\/j.jocmr.2026.102818_bib183","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocmr.2026.102818_bib184","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the children's oncology group","author":"Blanco","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib186","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/pgs.15.162","article-title":"Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines","volume":"17","author":"Hertz","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.jocmr.2026.102818_bib187","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/cncr.23534","article-title":"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer","volume":"112","author":"Blanco","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib188","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pgs.14.179","article-title":"Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma","volume":"16","author":"Reichwagen","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib189","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/CBI20110264","article-title":"ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia","volume":"36","author":"Semsei","year":"2012","journal-title":"Cell Biol Int"},{"issue":"24","key":"10.1016\/j.jocmr.2026.102818_bib190","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib191","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.5301\/JBM.5000041","article-title":"Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma","volume":"28","author":"Vivenza","year":"2013","journal-title":"Int J Biol Markers"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib192","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.15.61","article-title":"Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children","volume":"16","author":"Visscher","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jocmr.2026.102818_bib193","series-title":"Regulation of anti-oxidant and anti-apoptotic genes by progesterone in cardiomyocytes [Dissertation]","author":"Morrissy","year":"2007"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib194","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-015-3437-9","article-title":"Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients","volume":"152","author":"Vulsteke","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"1-2","key":"10.1016\/j.jocmr.2026.102818_bib195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxlet.2010.10.017","article-title":"Global gene expression profiles of MT knockout and wild-type mice in the condition of doxorubicin-induced cardiomyopathy","volume":"200","author":"Shuai","year":"2011","journal-title":"Toxicol Lett"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib196","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2015.63.4550","article-title":"CELF4 variant and anthracycline-related cardiomyopathy: a children's oncology group genome-wide association study","volume":"34","author":"Wang","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib197","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2013.50.3557","article-title":"Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group","volume":"32","author":"Wang","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jocmr.2026.102818_bib198","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","article-title":"Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer","volume":"332","author":"Lipshultz","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib199","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib200","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","article-title":"The pathogenesis of cardiac fibrosis","volume":"71","author":"Kong","year":"2014","journal-title":"Cell Mol life Sci CMLS"},{"key":"10.1016\/j.jocmr.2026.102818_bib201","first-page":"7","article-title":"Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes","author":"Knowles","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.jocmr.2026.102818_bib202","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.mri.2017.01.007","article-title":"Cardiac magnetic resonance tissue tracking in right ventricle: feasibility and normal values","volume":"38","author":"Truong","year":"2017","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.jocmr.2026.102818_bib203","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/713294","article-title":"Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer","volume":"2012","author":"Armenian","year":"2012","journal-title":"Cardiol Res Pract"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib204","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.2009.26.5751","article-title":"Cardiotoxicity after childhood cancer: beginning with the end in mind","volume":"28","author":"Lipshultz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jocmr.2026.102818_bib205","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-13-3490","article-title":"Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors","volume":"20","author":"Armenian","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib206","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"24","author":"Ehrhardt","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jocmr.2026.102818_bib207","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/10976640600713715","article-title":"Technical aspects of pediatric CMR","volume":"8","author":"Simonetti","year":"2006","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jocmr.2026.102818_bib208","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1532-429X-13-51","article-title":"The role of cardiovascular magnetic resonance in pediatric congenital heart disease","volume":"13","author":"Ntsinjana","year":"2011","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib209","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11899-007-0020-4","article-title":"Late effects of therapy for Hodgkin's lymphoma","volume":"2","author":"Adams","year":"2007","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11936-016-0466-6","article-title":"Late cardiotoxicity: issues for childhood cancer survivors","volume":"18","author":"Akam-Venkata","year":"2016","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib211","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3476(05)81668-3","article-title":"Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer","volume":"116","author":"Goorin","year":"1990","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.jocmr.2026.102818_bib212","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib213","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1053-4296(03)00026-2","article-title":"Radiation-associated cardiovascular disease: manifestations and management","volume":"13","author":"Adams","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"10.1016\/j.jocmr.2026.102818_bib214","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/pbc.20352","article-title":"Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention","volume":"44","author":"Adams","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"10.1016\/j.jocmr.2026.102818_bib215","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","article-title":"Anthracycline cardiotoxicity: from bench to bedside","volume":"26","author":"Gianni","year":"2008","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.jocmr.2026.102818_bib216","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1200\/JCO.2014.59.8052","article-title":"Collaborative research in childhood cancer survivorship: the current landscape","volume":"33","author":"Bhatia","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jocmr.2026.102818_bib217","first-page":"928","article-title":"Pathogenesis and prevention of doxorubicin cardiomyopathy","volume":"39","author":"Ferrans","year":"1997","journal-title":"Tsitologiia"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib218","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14503\/THIJ-14-4509","article-title":"Anthracycline treatment and ventricular remodeling in left ventricular assist device patients","volume":"42","author":"Segura","year":"2015","journal-title":"Tex Heart Inst J"},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib219","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096055","article-title":"Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up","volume":"9","author":"Lencova-Popelova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jocmr.2026.102818_bib220","doi-asserted-by":"crossref","DOI":"10.1534\/g3.119.400232","article-title":"Doxorubicin-induced cardiotoxicity in Collaborative Cross (CC) mice recapitulates individual cardiotoxicity in humans","author":"Zeiss","year":"2019","journal-title":"G3"},{"issue":"6","key":"10.1016\/j.jocmr.2026.102818_bib221","first-page":"955","article-title":"Overview of cardiac pathology in relation to anthracycline cardiotoxicity","volume":"62","author":"Ferrans","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib222","first-page":"24","article-title":"Quantitative assessment of radiotherapy-induced myocardial damage using MRI: a systematic review","volume":"9","author":"Omidi","year":"2023","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jocmr.2026.102818_bib223","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5352914","article-title":"Arterial stiffness in breast cancer patients treated with anthracycline and trastuzumab-based regimens","volume":"2018","author":"Yersal","year":"2018","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.jocmr.2026.102818_bib224","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12968-017-0390-2","article-title":"Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer","volume":"19","author":"Chan","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/eurheartj\/ehab635","article-title":"Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study","volume":"43","author":"Shenoy","year":"2021","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.jocmr.2026.102818_bib226","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1136\/heartjnl-2014-306364","article-title":"Cardiac masses and tumours","volume":"102","author":"Basso","year":"2016","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib227","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12968-020-00682-4","article-title":"SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance","volume":"22","author":"Leiner","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jocmr.2026.102818_bib228","first-page":"2022","article-title":"ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jocmr.2026.102818_bib229","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/JAHA.116.003368","article-title":"Pattern and prognostic implications of cardiac metastases among patients with advanced systemic cancer assessed with cardiac magnetic resonance imaging","volume":"5","author":"Pun","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.jocmr.2026.102818_bib230","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jcmg.2014.05.009","article-title":"Value of CMR for the differential diagnosis of cardiac masses","volume":"7","author":"Pazos-Lopez","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib231","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007829","article-title":"Assessment of cardiac masses by cardiac magnetic resonance imaging: histological correlation and clinical outcomes","volume":"8","author":"Mousavi","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib232","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2008.03.041","article-title":"Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction","volume":"52","author":"Weinsaft","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib233","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12968-019-0575-y","article-title":"Machine learning in cardiovascular magnetic resonance: basic concepts and applications","volume":"21","author":"Leiner","year":"2019","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib234","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3949\/ccjm.88a.19150","article-title":"Cardiac surveillance for anti-HER2 chemotherapy","volume":"88","author":"Collier","year":"2021","journal-title":"Cleve Clin J Med"},{"issue":"2","key":"10.1016\/j.jocmr.2026.102818_bib235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchf.2017.08.024","article-title":"Left ventricular dysfunction in cancer treatment: is it relevant?","volume":"6","author":"Kenigsberg","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jocmr.2026.102818_bib236","unstructured":"National Cancer Institute; Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 2017 [updated November 27, 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"21","key":"10.1016\/j.jocmr.2026.102818_bib237","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jocmr.2026.102818_bib238","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jocmr.2026.102818_bib239","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jocmr.2026.102818_bib240","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.jacc.2019.04.006","article-title":"Lessons from primary cardiac prevention trials during trastuzumab therapy: end of one size fits all","volume":"73","author":"Barac","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jocmr.2026.102818_bib241","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIR.0000000000001158","article-title":"Equity in cardio-oncology care and research: a scientific statement from the American heart association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jocmr.2026.102818_bib242","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2020.08.079","article-title":"Cardio-oncology education and training: JACC council perspectives","volume":"76","author":"Alvarez-Cardona","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib243","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12968-018-0429-z","article-title":"The growth and evolution of cardiovascular magnetic resonance: a 20-year history of the Society for Cardiovascular Magnetic Resonance (SCMR) annual scientific sessions","volume":"20","author":"Lee","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jocmr.2026.102818_bib244","first-page":"1","article-title":"Optimizing cardiovascular health in patients with cancer: a practical review of risk assessment, monitoring, and prevention of cancer treatment-related cardiovascular toxicity","volume":"40","author":"Dent","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.jocmr.2026.102818_bib245","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jacc.2025.07.036","article-title":"2025 ACC\/AHA\/ASE\/ASNC\/SCCT\/SCMR advanced training statement on advanced cardiovascular imaging: a report of the ACC competency management committee","volume":"87","author":"Baldassarre","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jocmr.2026.102818_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2025.102017","article-title":"Deep learning reconstruction for fast cardiovascular magnetic resonance imaging protocol: A comparative study with conventional cardiovascular magnetic resonance","volume":"28","author":"Hua","year":"2025","journal-title":"J Cardiovasc Magn Reson"}],"container-title":["Journal of Cardiovascular Magnetic Resonance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1097664726001365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1097664726001365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:11:28Z","timestamp":1793884288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1097664726001365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":246,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1097664726001365"],"URL":"https:\/\/doi.org\/10.1016\/j.jocmr.2026.102818","relation":{},"ISSN":["1097-6647"],"issn-type":[{"value":"1097-6647","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular magnetic resonance imaging in cardio-oncology: An expert consensus statement from the Society for Cardiovascular Magnetic Resonance. Endorsed by the International Cardio-Oncology Society (ICOS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiovascular Magnetic Resonance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocmr.2026.102818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Cardiovascular Magnetic Resonance.","name":"copyright","label":"Copyright"}],"article-number":"102818"}}